MORPHOLOGIC CHANGES OF DOXORUBICIN-SENSITIVE AND RESISTANT LOVO CELLS TREATED IN-VITRO BY CALCIUM CHANNELS BLOCKERS

  • Authors:
    • S DANCONA
    • M MAZZO
  • View Affiliations

  • Published online on: May 1, 1995     https://doi.org/10.3892/or.2.3.417
  • Pages: 417-421
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A morphological analysis by scanning electron microscopy (SEM) of the effect of two Ca++ channel blockers (verapamil and dilazep) on LoVo S (doxorubicin sensitive) and LoVo R (doxorubicin resistant) plated together with 3T3 in order to cause an experimental ground of metastasis was performed. Ca++ channel blockers have been previously tested alone and combined with doxorubicin. The increasing effect on the sensitivity of inherently antiblastic drug resistance and their possible role as antimetastatic agent according to the experiments of Tsuruo et al (Cancer Chemother Pharmacol 14: 30-33, 1985) is reported.

Related Articles

Journal Cover

May 1995
Volume 2 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
DANCONA S and DANCONA S: MORPHOLOGIC CHANGES OF DOXORUBICIN-SENSITIVE AND RESISTANT LOVO CELLS TREATED IN-VITRO BY CALCIUM CHANNELS BLOCKERS. Oncol Rep 2: 417-421, 1995
APA
DANCONA, S., & DANCONA, S. (1995). MORPHOLOGIC CHANGES OF DOXORUBICIN-SENSITIVE AND RESISTANT LOVO CELLS TREATED IN-VITRO BY CALCIUM CHANNELS BLOCKERS. Oncology Reports, 2, 417-421. https://doi.org/10.3892/or.2.3.417
MLA
DANCONA, S., MAZZO, M."MORPHOLOGIC CHANGES OF DOXORUBICIN-SENSITIVE AND RESISTANT LOVO CELLS TREATED IN-VITRO BY CALCIUM CHANNELS BLOCKERS". Oncology Reports 2.3 (1995): 417-421.
Chicago
DANCONA, S., MAZZO, M."MORPHOLOGIC CHANGES OF DOXORUBICIN-SENSITIVE AND RESISTANT LOVO CELLS TREATED IN-VITRO BY CALCIUM CHANNELS BLOCKERS". Oncology Reports 2, no. 3 (1995): 417-421. https://doi.org/10.3892/or.2.3.417